
    <rss version="2.0" xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd">
      <channel>
        <title>Articles tagged with OPDP from Medical Marketing and Media</title>
        <link>http://www.mmm-online.com/opdp/topic/13957/</link>
        <description>Articles tagged with OPDP from Medical Marketing and Media</description>
        <itunes:author>MMM</itunes:author>
        <itunes:subtitle></itunes:subtitle>
        <itunes:summary></itunes:summary>
        <itunes:owner>
            <itunes:name></itunes:name>
            <itunes:email>mmmsubs@haymarketmedia.com</itunes:email>
        </itunes:owner>
        <itunes:category text="BUSINESS">
            <itunes:category text="BUSINESS NEWS" /> 
        </itunes:category> 
        <itunes:image href='http://media.haymarketmedia.com/images/32/MMM_logo_28402_31022.gif'></itunes:image>
        <itunes:explicit>no</itunes:explicit>
  
        <item>
          <title>Business briefs: Aveo, Dynavax, Gilead, OPDP</title>
          <description>Aveo CRL says company&apos;s kidney drug information is uninterpretable; Dynavax has to find more hepatitis B clinical trial patients; Gilead&apos;s hep C drug gets priority status; OPDP slaps Janssen and Sigma Tau with untitled letters.</description>
          <link>http://www.mmm-online.com/business-briefs-aveo-dynavax-gilead-opdp/article/297144/</link>
          <pubDate>Mon, 10 Jun 2013 18:01:16 GMT</pubDate>
          <itunes:summary>Aveo CRL says company&apos;s kidney drug information is uninterpretable; Dynavax has to find more hepatitis B clinical trial patients; Gilead&apos;s hep C drug gets priority status; OPDP slaps Janssen and Sigma Tau with untitled letters.</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
        <item>
          <title>Business briefs: Teva, Celgene, Komen, Apple, OPDP</title>
          <description>Plan B age limits retained and rejected, Celgene drugs gets expanded indication, Komen cuts back on walks, Apple is policing medical apps, OPDP director&apos;s Q&amp;A</description>
          <link>http://www.mmm-online.com/business-briefs-teva-celgene-komen-apple-opdp/article/296684/</link>
          <pubDate>Thu, 06 Jun 2013 17:47:33 GMT</pubDate>
          <itunes:summary>Plan B age limits retained and rejected, Celgene drugs gets expanded indication, Komen cuts back on walks, Apple is policing medical apps, OPDP director&apos;s Q&amp;A</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
        <item>
          <title>Docs haven&apos;t mellowed on DTC, snap poll suggests</title>
          <description>The FDA wants to know how physician attitudes towards direct-to-consumer advertising have evolved since the agency last asked them, in 2002. If a snap poll by CMI/Compas is any indication, drug companies probably won&apos;t like the answers.</description>
          <link>http://www.mmm-online.com/docs-havent-mellowed-on-dtc-snap-poll-suggests/article/291567/</link>
          <pubDate>Wed, 01 May 2013 18:18:45 GMT</pubDate>
          <itunes:summary>The FDA wants to know how physician attitudes towards direct-to-consumer advertising have evolved since the agency last asked them, in 2002. If a snap poll by CMI/Compas is any indication, drug companies probably won&apos;t like the answers.</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
        <item>
          <title>OPDP takes an integrated approach to ad reviews</title>
          <description>FDA&apos;s Office of Prescription Drug Promotion is taking an integrated approach to reviewing promotional materials and shedding its consumer- and professional-directed silos.</description>
          <link>http://www.mmm-online.com/opdp-takes-an-integrated-approach-to-ad-reviews/article/283556/</link>
          <pubDate>Fri, 08 Mar 2013 16:13:32 GMT</pubDate>
          <itunes:summary>FDA&apos;s Office of Prescription Drug Promotion is taking an integrated approach to reviewing promotional materials and shedding its consumer- and professional-directed silos.</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
        <item>
          <title>AMARC Angst: Has FDA put pharma Facebook &quot;Likes&quot; in the crosshairs?</title>
          <description>What the agency writes in a recent warning letter to a dietary supplement firm is instructive with regard to &quot;Liking&quot; off-label posts.</description>
          <link>http://www.mmm-online.com/amarc-angst-has-fda-put-pharma-facebook-likes-in-the-crosshairs/article/283541/</link>
          <pubDate>Fri, 08 Mar 2013 14:47:43 GMT</pubDate>
          <itunes:summary>What the agency writes in a recent warning letter to a dietary supplement firm is instructive with regard to &quot;Liking&quot; off-label posts.</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
        <item>
          <title>Sequester cuts could snarl approvals for years</title>
          <description>With sequester cuts taking effect and no sign of a deal to end them in sight, FDA stands to lose 5% of its 2013 budget—though coming five months into the Federal fiscal year, it will feel more like 9%—and while the agency has said it has no plans at present for layoffs, it&apos;s certain the approvals process will slow as the agency absorbs the loss.</description>
          <link>http://www.mmm-online.com/sequester-cuts-could-snarl-approvals-for-years/article/283295/</link>
          <pubDate>Wed, 06 Mar 2013 19:20:47 GMT</pubDate>
          <itunes:summary>With sequester cuts taking effect and no sign of a deal to end them in sight, FDA stands to lose 5% of its 2013 budget—though coming five months into the Federal fiscal year, it will feel more like 9%—and while the agency has said it has no plans at present for layoffs, it&apos;s certain the approvals process will slow as the agency absorbs the loss.</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
        <item>
          <title>Razzed for lax DTC self-policing, PhRMA accentuates the positive</title>
          <description>PhRMA issued a terse response to a study claiming that ED drug advertisers more or less ignored the trade group&apos;s Guiding Principles for Direct to Consumer ads, a self-policing regime implemented in 2005 to fend off talk of a ban on drug ads.</description>
          <link>http://www.mmm-online.com/razzed-for-lax-dtc-self-policing-phrma-accentuates-the-positive/article/282684/</link>
          <pubDate>Fri, 01 Mar 2013 19:13:39 GMT</pubDate>
          <itunes:summary>PhRMA issued a terse response to a study claiming that ED drug advertisers more or less ignored the trade group&apos;s Guiding Principles for Direct to Consumer ads, a self-policing regime implemented in 2005 to fend off talk of a ban on drug ads.</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
        <item>
          <title>Merck finds &quot;dual modality&quot; in DTC helps viewers grasp risks</title>
          <description>A Merck study bolsters FDA&apos;s case for requiring that TV ads for prescription drugs present risks in text as well as the voiceover.</description>
          <link>http://www.mmm-online.com/merck-finds-dual-modality-in-dtc-helps-viewers-grasp-risks/article/274726/</link>
          <pubDate>Thu, 03 Jan 2013 20:54:48 GMT</pubDate>
          <itunes:summary>A Merck study bolsters FDA&apos;s case for requiring that TV ads for prescription drugs present risks in text as well as the voiceover.</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
        <item>
          <title>Company news: AstraZeneca, Alcon, Novo Nordisk</title>
          <description>AstraZeneca&apos;s 7,300 layoffs were not the last word for 2012, Alcon gets hit with an untitled letter from OPDP, and Novo creates an all-diabetic sports team</description>
          <link>http://www.mmm-online.com/company-news-astrazeneca-alcon-novo-nordisk/article/271323/</link>
          <pubDate>Wed, 05 Dec 2012 20:30:30 GMT</pubDate>
          <itunes:summary>AstraZeneca&apos;s 7,300 layoffs were not the last word for 2012, Alcon gets hit with an untitled letter from OPDP, and Novo creates an all-diabetic sports team</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
        <item>
          <title>With untitled letter, FDA signals press materials aren&apos;t exempt</title>
          <description>The FDA has issued a rare untitled letter concerning a pitch letter - a reminder that the agency does not consider press materials to be exempted from its oversight.</description>
          <link>http://www.mmm-online.com/with-untitled-letter-fda-signals-press-materials-arent-exempt/article/269255/</link>
          <pubDate>Tue, 20 Nov 2012 19:37:35 GMT</pubDate>
          <itunes:summary>The FDA has issued a rare untitled letter concerning a pitch letter - a reminder that the agency does not consider press materials to be exempted from its oversight.</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
      </channel>
    </rss>  
  